The current financial score of Scilex Holding Co is 7.18. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 7.64M, representing a year-over-year decrease of 22.78%, while its net profit experienced a year-over-year decrease of 33.31%.
The current valuation score of Scilex Holding Co is 8.89. Its current P/E ratio is -0.13, which is -3.34% below the recent high of -0.12 and -1903791.34% above the recent low of -2397.00.
No earnings forecast score is currently available for Scilex Holding Co. The Pharmaceuticals industry's average is 7.83.
The current price momentum score of Scilex Holding Co is 4.32. Currently, the stock price is trading between the resistance level at 5.92 and the support level at 4.57, making it suitable for range-bound swing trading.
The current institutional shareholding score of Scilex Holding Co is 3.00. The latest institutional shareholding proportion is 16.97%, representing a quarter-over-quarter increase of 16.47%. The largest institutional shareholder is James Simons, holding a total of 33.06K shares, representing 0.00% of shares outstanding, with 1320.00% increase in holdings.
The current risk assessment score of Scilex Holding Co is 2.60. The company's beta value is 1.69. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.